Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still ot
Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.
대표청구항▼
1. A compound of Formula (I) or (II): or ion pairs, salts, hydrates or solvates thereof, wherein:R1 is hydrogen, (C1-C4) alkyl, substituted (C1-C4) alkyl or (C1-C4) alkyl substituted with one or more fluorine atoms;R2 is alkyl, substituted alkyl, acyl, substituted acyl, halo, heteroalkyl, substitute
1. A compound of Formula (I) or (II): or ion pairs, salts, hydrates or solvates thereof, wherein:R1 is hydrogen, (C1-C4) alkyl, substituted (C1-C4) alkyl or (C1-C4) alkyl substituted with one or more fluorine atoms;R2 is alkyl, substituted alkyl, acyl, substituted acyl, halo, heteroalkyl, substituted heteroalkyl, —NO2, —N3, —OH, —S(O)kR100, —OR101, —NR102R103, —CONR104R105, —CO2R106 or —O2CR107;R3 is hydrogen, (C1-C3) alkyl, (C1-C3) substituted alkyl or (C1-C3) alkyl substituted with one or more fluorine atoms;R4 is hydrogen, methyl, ethyl, substituted aryl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, —OR108, —NR109R110, R5 is (C1-C4) alkyl or (C1-C4) substituted alkyl;R6 is hydrogen, (C1-C4) alkyl, substituted (C1-C4) alkyl, benzyl or substituted benzyl;R7 is (C1-C4) alkyl, substituted (C1-C4) alkyl, benzyl or substituted benzyl;R8 is hydrogen, OH, ═O, (C1-C4) alkyl, (C1-C4) substituted alkyl, —CO2R114 or —CONR115R116;R9 is hydrogen, OH, ═O, (C1-C4) alkyl, (C1-C4) substituted alkyl, —CO2R117 or —CONR118R119;R10 is hydrogen, OH, ═O, (C1-C4) alkyl, (C1-C4) substituted alkyl, —CO2R120 or —CONR121R122;R11 is hydrogen, (C1-C3) alkyl or (C1-C3) alkyl substituted with one or more fluorine atoms;R12 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, —S(O)mR111 or —CONR112R113;R100-R122 are independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;m and k are independently 0, 1 or 2;n is 0, 1, 2 or 3; andprovided that when R11 is hydrogen or (C1-C3) alkyl, R1 is (C1-C4) alkyl substituted with one or more fluorine atoms; and R109 and R110 are not substituted with fluorine unless R12 is acyl or substituted acyl. 2. The compound of claim 1, wherein R1 is hydrogen or (C1-C4) alkyl substituted with one or more fluorine atoms, n is 0, R3 is hydrogen or (C1-C3) alkyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 3. The compound of claim 1, wherein R1 is hydrogen, methyl or methyl substituted with one or more fluorine atoms, R2 is alkyl, halo, —OR101, n is 1, R3 is hydrogen, methyl or allyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 4. The compound of claim 1, wherein R1 is hydrogen, methyl or methyl substituted with one or more fluorine atoms, n is 0, R3 is hydrogen, methyl or allyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 5. The compound of claim 1, wherein R1 is hydrogen or (C1-C4) alkyl substituted with one or more fluorine atoms, n is 0,R3 is hydrogen or (C1-C3) alkyl, R4 is R8, R9 and R10 are hydrogen, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 6. The compound of claim 1, wherein R1 is hydrogen, methyl or methyl substituted with one or more fluorine atoms, R2 is alkyl, halo, —OR101, n is 1,R3 is hydrogen, methyl or allyl, R4 is R8, R9 and R10 are hydrogen, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 7. The compound of claim 1, wherein R1 is hydrogen, methyl or methyl substituted with one or more fluorine atoms, n is 0, R3 is hydrogen, methyl or allyl, R4 is R8, R9 and R10 are hydrogen, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 8. The compound of claim 1, wherein R1 is hydrogen, methyl or methyl substituted with one or more fluorine atoms, R2 is alkyl, acyl, halo, —NO2, —OH, —S(O)kR100, —OR101, —NR102R103, —CONR104R105, —CO2R106 or —O2CR107, n is 1,R3 is hydrogen, methyl or allyl, R4 is R8, R9 and R10 are hydrogen, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 9. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is allyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 10. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is methyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen. 11. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is methyl, R4 is R8, R9 and R10 are hydrogen, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen. 12. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is allyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is substituted alkyl. 13. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is allyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen. 14. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is allyl, R4 is —NR109R110, and R12 is substituted acyl. 15. The compound of claim 1, wherein R1 is hydrogen, n is 0,R3 is allyl, R4 is —NR109R110, and R12 is —CONR112R113. 16. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is methyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is substituted alkyl. 17. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is methyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen. 18. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is methyl, R4 is —NR109R110, and R12 is substituted acyl. 19. The compound of claim 1, wherein R1 is hydrogen, n is 0,R3 is methyl, R4 is —NR109R110, and R12 is —CONR112R113. 20. The compound of claim 1, wherein R1 is hydrogen or (C1-C4) alkyl substituted with one or more fluorine atoms, n is 0, R3 is hydrogen or (C1-C3) alkyl, R4 is —NR109R110 or substituted alkyl, and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 21. The compound of claim 1, wherein R1 is hydrogen, methyl or methyl substituted with one or more fluorine atoms, R2 is alkyl, halo, —OR101, n is 1, R3 is hydrogen, methyl or allyl, R4 is —NR109R110, and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 22. The compound of claim 1, wherein R1 is hydrogen, methyl or methyl substituted with one or more fluorine atoms, n is 0,R3 is hydrogen, methyl or allyl, R4 is —NR109R110, R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 23. The compound of claim 1, wherein R1 is hydrogen, methyl or methyl substituted with one or more fluorine atoms, R2 is alkyl, acyl, halo, —NO2, —OH, —S(O)kR100, —R101, —NR102R103, —CONR104R105, —CO2R106 or —O2CR107, n is 1, R3 is hydrogen, methyl or allyl, R4 is —NR109R110 or substituted alkyl, R8, R9 and R10 are hydrogen, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen, substituted alkyl, substituted acyl or —CONR112R113. 24. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is allyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is —CONR112R113. 25. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is methyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen. 26. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is methyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is substituted alkyl. 27. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is allyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is substituted alkyl. 28. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is allyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is hydrogen. 29. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is methyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is substituted acyl. 30. The compound of claim 1, wherein R1 is hydrogen, n is 0, R3 is methyl, R4 is —NR109R110, R11 is methyl substituted with one or more fluorine atoms and R12 is —CONR112R113.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (89)
Sauer Gerhard (Berlin DEX) Schrter Bernd (Berlin DEX) Brumby Thomas (Berlin DEX) Wachtel Helmut (Berlin DEX) Lschmann Peter A. (Berlin DEX), 2, 13-disubstituted ergolines, their production and use in pharmaceutical agents.
Sauer Gerhard (Berlin DEX) Wachtel Helmut (Berlin DEX) Lschmann Peter A. (Berlin DEX), 2,14-disubstituted ergolines, their production and use in pharmaceutical compositions.
Brumby Thomas (Berlin DEX) Sauer Gerhard (Berlin DEX) Heindl Josef (Berlin DEX) Turner Jonathan (Berlin DEX) Khne Gerhard (Berlin DEX) Wachtel Helmut (Berlin DEX), 2-substituted ergolines.
Cincotta Anthony H. (Andover MA) Meier Albert H. (Baton Rouge LA) Wilson John M. (Charlestown MA), Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metab.
Yuzhakov Vadim Vladimirovich ; Sherman Faiz Feisal ; Owens Grover David ; Gartstein Vladimir, Apparatus and method for using an intracutaneous microneedle array.
Oh, Jong Eun; Lee, Keon Hyoung; Park, Tae Gwan; Nam, Yoon Sung, Controlled drug delivery system using the conjugation of drug to biodegradable polyester.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Marshall Lucia G. I. (St. Charles MO) Patel Kanaiyalal R. (St. Louis MO) Roufa Dikla G. (St. Louis MO), Controlled release formulations of trophic factors in ganglioside-lipsome vehicle.
Yatvin Milton B. ; Stowell Michael H. B. ; Gallicchio Vincent S. ; Meredith Michael J., Covalent microparticle-drug conjugates for biological targeting.
Kobel Hans (Basel CHX) Sanglier Jean-Jacques (Oberwil CHX) Tscherter Hans (Allschwil CHX) Bolliger Georg (Binningen CHX), Ergot cyclic peptide alkaloids having a venotonizing effect, useful for treating orthostatic hypotension.
Mohr Judy M. (Menlo Park CA) Baker Richard W. (Palo Alto CA) Nakaji Lisa A. (San Jose CA), Liquid reservoir transdermal patch for the administration of ketorolac.
Calanchi Massimo,ITX ; Zema Marco,ITX ; Brunetti Gabriele,ITX ; Giorgetti Enzo,ITX, Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colon.
Santus Giancarlo (Milan ITX) Bilato Ettore (Padua ITX) Lazzarini Gabriele (Pero ITX), Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension.
Le Grazie Cristina (Milan ITX), Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutic.
Venkateshwaran Srinivasan ; Fikstad David ; Ebert Charles D., Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Saikawa, Akira; Igari, Yasutaka; Hata, Yoshio; Yamamoto, Kazumichi, Sustained release compositions, process for producing the same and utilization thereof.
Bodmer David (Klingnau CHX) Fong Jones W. (Parsippany NJ) Kissel Thomas (Staufen DEX) Maulding Hawkins V. (Mendham NJ) Nagele Oskar (Sissach CHX) Pearson Jane E. (Ogendensburg NJ), Sustained release formulations of water soluble peptides.
Unger Evan C. ; Fritz Thomas A. ; Matsunaga Terry ; Ramaswami VaradaRajan ; Yellowhair David ; Wu Guanli, Targeted gas and gaseous precursor-filled liposomes.
Friend David R. ; Ng Steve ; Sarabia Rafael E. ; Weber Thomas P. ; Geoffroy Jean-Marie, Taste-masked microcapsule compositions and methods of manufacture.
Norris James ; Clawson Gary ; Westwater Caroline ; Schofield David ; Schmidt Michael ; Hoel Brian ; Dolan Joseph ; Pan Wei-Hua, Tissue-specific and pathogen-specific toxic agents and ribozymes.
DeSantis ; Jr. Louis ; Sallee Verney L. ; McLaughlin Marsha A. ; Maniar Manoj L., Use of cabergoline and related ergoline derivatives for controlling intraocular pressure.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.